- "TAR-200 is a miniature, pretzel-shaped drug-device duo containing a chemotherapy drug, gemcitabine, which is inserted into the bladder through a catheter. Once inside the bladder, the TAR-200 slowly and consistently releases the gemcitabine into the organ for three weeks per treatment cycle."
- Phase 2 Clinical Trial
- 85 patients with high-risk non-muscle-invasive bladder cancer
- "treated patients with TAR-200 every three weeks for six months, and then four times a year for the next two years"
- 70/85 patients—the cancer disappeared and still gone 1yr later in almost 50% patients
- FDA granted TAR-200 a New Drug Application Priority Review
- "TAR-200 is a miniature, pretzel-shaped drug-device duo containing a chemotherapy drug, gemcitabine, which is inserted into the bladder through a catheter. Once inside the bladder, the TAR-200 slowly and consistently releases the gemcitabine into the organ for three weeks per treatment cycle."
- Phase 2 Clinical Trial
- 85 patients with high-risk non-muscle-invasive bladder cancer
- "treated patients with TAR-200 every three weeks for six months, and then four times a year for the next two years"
- 70/85 patients—the cancer disappeared and still gone 1yr later in almost 50% patients
- FDA granted TAR-200 a New Drug Application Priority Review
- Johnson & Johnson manufactures TAR-200